You can find plenty of affordable stocks that offer solid long-term growth prospects. If you're interested in the healthcare ...

RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.

With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...